Middle-aged smokers have a higher risk of developing dementia

Published Date: 02 Mar 2023

Middle-aged smokers are more likely to report memory loss and confusion than non-smokers.

Read Full News

Latest News

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

Todays Updates

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Todays Updates

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Latest News

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

News All Time

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL Noah Stansfield

The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education Charuta Joshi, MD, Isabella Ciccone, MPH

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

NeurologyLive® Friday 5 — February 6, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns Isabella Ciccone, MPH

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Cladribine Tablets Reduce Treatment Switches, Outpatient Visits, and Health Care Costs in Multiple Sclerosis Isabella Ciccone, MPH

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

Innovative Trial Employs Novel PET Imaging to Track Cladribine’s Effect on Microglial Activation Louie Pasculli

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Recommended News For You

PSMA PET Beats MRI in Prostate Cancer Staging Study

How Do Younger People Fare With Stool Tests for CRC Screening?

Radiation therapy for patients with breast cancer

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

X-ray and radar technology combined to reduce cancer screening risks

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

Recommended Articles For You

Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment 

Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia 

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer 

Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.

2.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

3.

Massachusetts nurses with brain tumors: Department of Public Health 'in communication' with Newton-Wellesley

4.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

5.

Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment

1.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

2.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

3.

Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment

4.

Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment

5.

Unveiling the Mystery of Castleman's Disease: A Journey to Better Health

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

2.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

3.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

4.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot